InvestorLens

AVLN — AVALYN PHARMACEUTICALS INC

Public company

Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying AVLN?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 2 buying vs 0 selling last quarter
65
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their AVLN position last quarter, 2 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (George Soros, Ken Griffin)
  • +2 tracked investors reported holding AVLN at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About AVALYN PHARMACEUTICALS INC (AVLN)

AVALYN PHARMACEUTICALS INC (AVLN) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $32M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in AVLN

100
/100
Strong Institutional Accumulation
Added / Increased2
Reduced0
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track AVLN

13
/100
Undiscovered
2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded
151015+

AVLN Ownership Composition

How AVALYN PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
99% of tracked value
Institutions
2
tracked investors
Total Reported
$31.9M
combined 13F value
Types2
  • Multi-Strategy / Quant99.0%
  • Macro1.0%
Multi-Strategy / Quant(1)
99.0%
Macro(1)
1.0%

Tracked investors currently reporting AVLN

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    959.1K
    Value
    $31.6M
    % Portfolio
    0.00%
  • George SorosJun 30, 2026
    Soros Fund Management
    Shares
    10K
    Value
    $329.2K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold AVLN?
2 tracked institutional investors disclosed a position in AVLN (AVALYN PHARMACEUTICALS INC) in their most recent 13F filing.
Who is the largest institutional holder of AVLN?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in AVLN, valued at $32M.
Did institutional ownership of AVLN increase or decrease?
Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 fully exited AVLN.
Where does this AVLN ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
AVLN (AVALYN PHARMACEUTICALS INC) — Institutional Holders & — InvestorLens